Clinical experiences with recombinant activated factor VII for managing uncontrolled hemorrhage in non-hemophilic patients

Chi Cheng Li, Ji Hung Wang, Yen Ta Huang, Han Yu Huang, Tso Fu Wang, Sung Chao Chu, Chao Yuan Yao, Yi Feng Wu, Szu Chin Li, Kuan Po Huang, Wei Han Huang, Ming Ching Shen, Ruey Ho Kao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Recombinant activated factor VII (rFVIIa) is a novel hemostatic agent originally developed to treat hemophilia patients who had developed inhibitors with bleeding. Its role in treating uncontrolled bleeding in patients without pre-existing coagulation abnormalities has not been well established. We herein report our experiences with its use in non-hemophilic patients. Patients and Methods: Four patients, aged 33 to 94 years, with different underlying diseases were treated with rFVIIa for uncontrolled, life-threatening hemorrhage. rFVIIa was initially administered by intravenous bolus injection at 80-100 μg/kg. Doses were adjusted according to clinical response. Results: Clinical response with significant hemostasis was evident in three patients after initial treatment. One patient was unresponsive to rFVIIa treatment and died of uncontrolled bleeding. Of those who achieved initial hemostasis, two died of their underlying diseases. One had recurrent bleeding controlled by subsequent multiple doses of rFVIIa, but she died of acute myocardial infarction, a thromboembolic complication that probably arose from the use of rFVIIa. Conclusion: Our results suggest that rFVIIa could play a role in the management of bleeding other than congenital coagulation disorder. However, clinical hemostatic effects that do not translate into a survival benefit require further study, especially with regard to appropriate timing for clinical use. Its potential risk, especially that of thromboembolism when treating bleeding in elderly patients, warrants further investigation.

Original languageEnglish
Pages (from-to)220-225
Number of pages6
JournalTzu Chi Medical Journal
Volume19
Issue number4
DOIs
Publication statusPublished - Jan 1 2007
Externally publishedYes

Fingerprint

Factor VIIa
Hemorrhage
Hemostatics
Hemostasis
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Thromboembolism
Hemophilia A
recombinant FVIIa
Intravenous Injections
Myocardial Infarction
Survival
Therapeutics

Keywords

  • Hemophilia
  • Hemorrhage
  • Hemostasis
  • Recombinant factor VIIa (rFVIIa)
  • Thromboembolism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical experiences with recombinant activated factor VII for managing uncontrolled hemorrhage in non-hemophilic patients. / Li, Chi Cheng; Wang, Ji Hung; Huang, Yen Ta; Huang, Han Yu; Wang, Tso Fu; Chu, Sung Chao; Yao, Chao Yuan; Wu, Yi Feng; Li, Szu Chin; Huang, Kuan Po; Huang, Wei Han; Shen, Ming Ching; Kao, Ruey Ho.

In: Tzu Chi Medical Journal, Vol. 19, No. 4, 01.01.2007, p. 220-225.

Research output: Contribution to journalArticle

Li, CC, Wang, JH, Huang, YT, Huang, HY, Wang, TF, Chu, SC, Yao, CY, Wu, YF, Li, SC, Huang, KP, Huang, WH, Shen, MC & Kao, RH 2007, 'Clinical experiences with recombinant activated factor VII for managing uncontrolled hemorrhage in non-hemophilic patients', Tzu Chi Medical Journal, vol. 19, no. 4, pp. 220-225. https://doi.org/10.1016/S1016-3190(10)60019-5
Li, Chi Cheng ; Wang, Ji Hung ; Huang, Yen Ta ; Huang, Han Yu ; Wang, Tso Fu ; Chu, Sung Chao ; Yao, Chao Yuan ; Wu, Yi Feng ; Li, Szu Chin ; Huang, Kuan Po ; Huang, Wei Han ; Shen, Ming Ching ; Kao, Ruey Ho. / Clinical experiences with recombinant activated factor VII for managing uncontrolled hemorrhage in non-hemophilic patients. In: Tzu Chi Medical Journal. 2007 ; Vol. 19, No. 4. pp. 220-225.
@article{c5df0877414442b1a17645202b669421,
title = "Clinical experiences with recombinant activated factor VII for managing uncontrolled hemorrhage in non-hemophilic patients",
abstract = "Objective: Recombinant activated factor VII (rFVIIa) is a novel hemostatic agent originally developed to treat hemophilia patients who had developed inhibitors with bleeding. Its role in treating uncontrolled bleeding in patients without pre-existing coagulation abnormalities has not been well established. We herein report our experiences with its use in non-hemophilic patients. Patients and Methods: Four patients, aged 33 to 94 years, with different underlying diseases were treated with rFVIIa for uncontrolled, life-threatening hemorrhage. rFVIIa was initially administered by intravenous bolus injection at 80-100 μg/kg. Doses were adjusted according to clinical response. Results: Clinical response with significant hemostasis was evident in three patients after initial treatment. One patient was unresponsive to rFVIIa treatment and died of uncontrolled bleeding. Of those who achieved initial hemostasis, two died of their underlying diseases. One had recurrent bleeding controlled by subsequent multiple doses of rFVIIa, but she died of acute myocardial infarction, a thromboembolic complication that probably arose from the use of rFVIIa. Conclusion: Our results suggest that rFVIIa could play a role in the management of bleeding other than congenital coagulation disorder. However, clinical hemostatic effects that do not translate into a survival benefit require further study, especially with regard to appropriate timing for clinical use. Its potential risk, especially that of thromboembolism when treating bleeding in elderly patients, warrants further investigation.",
keywords = "Hemophilia, Hemorrhage, Hemostasis, Recombinant factor VIIa (rFVIIa), Thromboembolism",
author = "Li, {Chi Cheng} and Wang, {Ji Hung} and Huang, {Yen Ta} and Huang, {Han Yu} and Wang, {Tso Fu} and Chu, {Sung Chao} and Yao, {Chao Yuan} and Wu, {Yi Feng} and Li, {Szu Chin} and Huang, {Kuan Po} and Huang, {Wei Han} and Shen, {Ming Ching} and Kao, {Ruey Ho}",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/S1016-3190(10)60019-5",
language = "English",
volume = "19",
pages = "220--225",
journal = "Tzu Chi Medical Journal",
issn = "1016-3190",
publisher = "財團法人中華民國佛教慈濟慈善事業基金會",
number = "4",

}

TY - JOUR

T1 - Clinical experiences with recombinant activated factor VII for managing uncontrolled hemorrhage in non-hemophilic patients

AU - Li, Chi Cheng

AU - Wang, Ji Hung

AU - Huang, Yen Ta

AU - Huang, Han Yu

AU - Wang, Tso Fu

AU - Chu, Sung Chao

AU - Yao, Chao Yuan

AU - Wu, Yi Feng

AU - Li, Szu Chin

AU - Huang, Kuan Po

AU - Huang, Wei Han

AU - Shen, Ming Ching

AU - Kao, Ruey Ho

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Objective: Recombinant activated factor VII (rFVIIa) is a novel hemostatic agent originally developed to treat hemophilia patients who had developed inhibitors with bleeding. Its role in treating uncontrolled bleeding in patients without pre-existing coagulation abnormalities has not been well established. We herein report our experiences with its use in non-hemophilic patients. Patients and Methods: Four patients, aged 33 to 94 years, with different underlying diseases were treated with rFVIIa for uncontrolled, life-threatening hemorrhage. rFVIIa was initially administered by intravenous bolus injection at 80-100 μg/kg. Doses were adjusted according to clinical response. Results: Clinical response with significant hemostasis was evident in three patients after initial treatment. One patient was unresponsive to rFVIIa treatment and died of uncontrolled bleeding. Of those who achieved initial hemostasis, two died of their underlying diseases. One had recurrent bleeding controlled by subsequent multiple doses of rFVIIa, but she died of acute myocardial infarction, a thromboembolic complication that probably arose from the use of rFVIIa. Conclusion: Our results suggest that rFVIIa could play a role in the management of bleeding other than congenital coagulation disorder. However, clinical hemostatic effects that do not translate into a survival benefit require further study, especially with regard to appropriate timing for clinical use. Its potential risk, especially that of thromboembolism when treating bleeding in elderly patients, warrants further investigation.

AB - Objective: Recombinant activated factor VII (rFVIIa) is a novel hemostatic agent originally developed to treat hemophilia patients who had developed inhibitors with bleeding. Its role in treating uncontrolled bleeding in patients without pre-existing coagulation abnormalities has not been well established. We herein report our experiences with its use in non-hemophilic patients. Patients and Methods: Four patients, aged 33 to 94 years, with different underlying diseases were treated with rFVIIa for uncontrolled, life-threatening hemorrhage. rFVIIa was initially administered by intravenous bolus injection at 80-100 μg/kg. Doses were adjusted according to clinical response. Results: Clinical response with significant hemostasis was evident in three patients after initial treatment. One patient was unresponsive to rFVIIa treatment and died of uncontrolled bleeding. Of those who achieved initial hemostasis, two died of their underlying diseases. One had recurrent bleeding controlled by subsequent multiple doses of rFVIIa, but she died of acute myocardial infarction, a thromboembolic complication that probably arose from the use of rFVIIa. Conclusion: Our results suggest that rFVIIa could play a role in the management of bleeding other than congenital coagulation disorder. However, clinical hemostatic effects that do not translate into a survival benefit require further study, especially with regard to appropriate timing for clinical use. Its potential risk, especially that of thromboembolism when treating bleeding in elderly patients, warrants further investigation.

KW - Hemophilia

KW - Hemorrhage

KW - Hemostasis

KW - Recombinant factor VIIa (rFVIIa)

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=38049015886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049015886&partnerID=8YFLogxK

U2 - 10.1016/S1016-3190(10)60019-5

DO - 10.1016/S1016-3190(10)60019-5

M3 - Article

AN - SCOPUS:38049015886

VL - 19

SP - 220

EP - 225

JO - Tzu Chi Medical Journal

JF - Tzu Chi Medical Journal

SN - 1016-3190

IS - 4

ER -